{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01048268: Phase 1/Phase 2 Interventional Completed Diabetes Mellitus
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03587311: Phase 2 Interventional Active, not recruiting Fallopian Tube Endometrioid Adenocarcinoma
(2018)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT02472977: Phase 1/Phase 2 Interventional Terminated Solid Tumor
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00001789: Phase 2 Interventional Completed Glomerulonephritis, Membranoproliferative
(1999)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
INN:cimaglermin alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:DENINTUZUMAB [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03120949: Phase 3 Interventional Completed Rheumatoid Arthritis
(2017)
Source URL:
Class:
PROTEIN
